At Boreal, we are committed to improving cancer patient care through development of research tools and diagnostic tests based on monitoring of circulating tumor DNA in plasma.
Boreal’s OnTarget™ platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTarget™ assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs.
Boreal’s OnTarget™ platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTarget™ assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs.
Location: Canada, British Columbia, Electoral Area A
Employees: 11-50
Total raised: $18M
Founded date: 2007
Investors 3
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Illumina V... | illuminaVe... |
| - | In-Q-Tel | iqt.org |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.10.2013 | Series C | $18M | - |
Mentions in press and media 4
| Date | Title | Description |
| 25.06.2015 | Single-cell technologies advance the value of genomics | Single-cell technologies advance the value of genomics 25-06-2015 Biologists are looking to extract as much information as possible from small amounts of valuable biological material, and to understand biological responses at higher levels ... |
| 25.06.2015 | Single-cell technologies advance the value of genomics | Biologists are looking to extract as much information as possible from small amounts of valuable biological material, and to understand biological responses at higher levels of resolution. The Genome Analysis Centre (TGAC) has been working ... |
| 07.10.2013 | Boreal Genomics Secures $18M in Series C | LOS ALTOS, CA, Privately held provider of technology for non-invasive genomic profiling of tumors from blood plasma of cancer patients, announced today the completion of an $18 million Series C financing round. >> Click here for mo... |
| 05.10.2013 | Boreal Genomics Completes $18M Series C Financing | Boreal Genomics, a Los Altos, CA-based provider of technology for non-invasive genomic profiling of tumors from blood plasma of cancer patients, completed an $18m Series C financing. Backers included existing investors ARCH Venture Partners... |